Literature DB >> 10069455

Mismatch repair and differential sensitivity of mouse and human cells to methylating agents.

O Humbert1, S Fiumicino, G Aquilina, P Branch, S Oda, A Zijno, P Karran, M Bignami.   

Abstract

The long-patch mismatch repair pathway contributes to the cytotoxic effect of methylating agents and loss of this pathway confers tolerance to DNA methylation damage. Two methylation-tolerant mouse cell lines were identified and were shown to be defective in the MSH2 protein by in vitro mismatch repair assay. A normal copy of the human MSH2 gene, introduced by transfer of human chromosome 2, reversed the methylation tolerance. These mismatch repair defective mouse cells together with a fibroblast cell line derived from an MSH2-/- mouse, were all as resistant to N-methyl-N-nitrosourea as repair-defective human cells. Although long-patch mismatch repair-defective human cells were 50- to 100-fold more resistant to methylating agents than repair-proficient cells, loss of the same pathway from mouse cells conferred only a 3-fold increase. This discrepancy was accounted for by the intrinsic N-methyl-N-nitrosourea resistance of normal or transformed mouse cells compared with human cells. The >20-fold differential resistance between mouse and human cells could not be explained by the levels of either DNA methylation damage or the repair enzyme O6-methylguanine-DNA methyltransferase. The resistance of mouse cells to N-methyl-N-nitrosourea was selective and no cross-resistance to unrelated DNA damaging agents was observed. Pathways of apoptosis were apparently intact and functional after exposure to either N-methyl-N-nitrosourea or ultraviolet light. Extracts of mouse cells were found to perform 2-fold less long-patch mismatch repair. The reduced level of mismatch repair may contribute to their lack of sensitivity to DNA methylation damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069455     DOI: 10.1093/carcin/20.2.205

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression.

Authors:  Gulcin Tezcan; Berrin Tunca; Ahmet Bekar; Ferah Budak; Saliha Sahin; Gulsah Cecener; Unal Egeli; Mevlut Ozgur Taskapılıoglu; Hasan Kocaeli; Sahsine Tolunay; Hulusi Malyer; Cevdet Demir; Gulendam Tumen
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

2.  Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.

Authors:  Kimiko Ishiguro; Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

3.  Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis.

Authors:  Robert A Screaton; Stephan Kiessling; Owen J Sansom; Catherine B Millar; Kathryn Maddison; Adrian Bird; Alan R Clarke; Steven M Frisch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

Review 4.  Peto's Paradox: evolution's prescription for cancer prevention.

Authors:  Aleah F Caulin; Carlo C Maley
Journal:  Trends Ecol Evol       Date:  2011-04       Impact factor: 17.712

5.  Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

Authors:  J Thulesen; B Hartmann; K J Hare; H Kissow; C Ørskov; J J Holst; S S Poulsen
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  MSH2 is essential for the preservation of genome integrity and prevents homeologous recombination in the moss Physcomitrella patens.

Authors:  Bénédicte Trouiller; Didier G Schaefer; Florence Charlot; Fabien Nogué
Journal:  Nucleic Acids Res       Date:  2006-01-05       Impact factor: 16.971

7.  Peto's paradox revisited: theoretical evolutionary dynamics of cancer in wild populations.

Authors:  Benjamin Roche; Kathleen Sprouffske; Hassan Hbid; Dorothée Missé; Frédéric Thomas
Journal:  Evol Appl       Date:  2012-11-22       Impact factor: 5.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.